It beat top and bottom line. Sentiment was negative, so that set a low bar that they beat. You're starting to see the benefits of their AI capex with cloud revenue up 35% and the core search business is okay. Is not surprised that shares are up (over 5%) this morning without pulling back. Institutional buyers will re-enter this name.
They beat top and bottom and raised guidance. A nice quarter. Their key drugs were way up. They have a strong pipeline.